Proxy Votes Now

Home › Funds › Nationwide › Nationwide Bailard Cognitive Value Fund

Nationwide Bailard Cognitive Value Fund (NWHDX) proxy voting record 2025-2026

Fund family: Nationwide · Filed by NATIONWIDE MUTUAL FUNDS (CIK 1048702) · SEC series S000041092

Share classes and tickers: NWHDX (C000127572), NWHEX (C000127573), NWHFX (C000127574), NWHGX (C000127575), NWHHX (C000127576)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 2,327 with, 13 against, 0 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 10 FOR, 1 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Nationwide as a whole

The same two figures as Nationwide’s manager page (159,461 ballot items across 59 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsNationwideItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)85.7%2,27294.0%138,376
Backed environmental and social shareholder proposals at US companiesn/a27.3%1,864

Where this fund voted differently from most Nationwide funds

Each ballot item this fund voted is set against the votes of the other Nationwide funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Nationwide funds on 160 items (9.9% of the 1,623 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Nationwide fundsMgmtResult
Taylor Morrison Home Corporation2026-05-21Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AgainstFOR — 8 of 8 Nationwide fundsAgainst—
ePlus inc.2025-09-16To approve, on an advisory basis, our named executive officer compensation.AgainstFOR — 7 of 7 Nationwide fundsAgainstApproved, 89.6% support
Sanmina Corporation2026-03-09Shareholder To consider and vote upon the stockholder proposal entitled "Independent Board Chairman," requesting that the Board of Directors adopt a policy and amend governing documents as necessary in order that two separate people hold the office of the Chairman and the office of the CEO.ForAGAINST — 6 of 6 Nationwide fundsAgainstFailed (calculated), 11.9% support
Sanmina Corporation2026-03-09To elect eight directors of Sanmina Corporation: Mythili SankaranAgainstFOR — 6 of 6 Nationwide fundsAgainstPassed (calculated), 56.9% support
Heritage Insurance Holdings, Inc.2026-06-10Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive OfficersAgainstFOR — 6 of 6 Nationwide fundsAgainstPassed (calculated), 93.9% support
Winmark Corporation2026-04-22Advisory vote to approve executive compensation.AgainstFOR — 6 of 6 Nationwide fundsAgainstPassed (calculated), 96.7% support
Citi Trends, Inc.2026-06-10An advisory vote to approve, on a non-binding basis, the compensation of our named executive officers as set forth in the proxy statement.AgainstFOR — 6 of 6 Nationwide fundsAgainstApproved, 99.1% support
Designer Brands Inc.2026-06-17Advisory vote to approve the compensation paid to our named executive officers in the fiscal year ended January 31, 2026.AgainstFOR — 6 of 6 Nationwide fundsAgainstApproved, 97.4% support
Ryder System, Inc.2026-05-01Shareholder To vote, on an advisory basis, on a shareholder proposal regarding an independent board chair.ForAGAINST — 5 of 5 Nationwide fundsAgainstFailed (calculated), 21.1% support
Mirum Pharmaceuticals, Inc.2026-06-15To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Lon Cardon, Ph.D., FMedSciWithholdFOR — 5 of 5 Nationwide fundsAgainstElected, 85.3% support
Mirum Pharmaceuticals, Inc.2026-06-15To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: William FaireyWithholdFOR — 5 of 5 Nationwide fundsAgainstElected, 86.8% support
Associated Banc-Corp2026-04-28The ratification of the selection of KPMG LLP as the independent registered public accounting firm for Associated Banc-Corp for the year ending December 31, 2026.AgainstFOR — 5 of 5 Nationwide fundsAgainstApproved, 97.8% support
Bread Financial Holdings, Inc.2026-05-19ADVISORY VOTE ON EXECUTIVE COMPENSATIONAgainstFOR — 5 of 5 Nationwide fundsAgainstApproved, 92.0% support
Callaway Golf Company2026-05-21To approve, on an advisory basis, the compensation of the Company's named executive officersAgainstFOR — 5 of 5 Nationwide fundsAgainstApproved, 93.9% support
Tompkins Financial Corporation2026-05-19Advisory approval of the compensation paid to the Company's Named Executive Officers.AgainstFOR — 5 of 5 Nationwide fundsAgainstApproved, 97.7% support
Capital City Bank Group, Inc.2026-04-21To consider and approve, on a non-binding advisory basis, the compensation of our named executive officers.AgainstFOR — 5 of 5 Nationwide fundsAgainstPassed (calculated), 98.5% support
American Integrity Insurance Group, Inc.2026-06-11To approve, on an advisory basis, the compensation of the Company's named executive officers; andAgainstFOR — 5 of 5 Nationwide fundsAgainstPassed (calculated), 97.9% support
Greenlight Capital Re, Ltd.2025-07-29To consider and cast a non-binding advisory vote on a resolution approving the compensation of the Company's named executive officers as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission.AgainstFOR — 5 of 5 Nationwide fundsAgainstPassed (calculated), 91.8% support
Oil States International, Inc.2026-05-12TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S EXECUTIVE COMPENSATION.AgainstFOR — 5 of 5 Nationwide fundsAgainstPassed (calculated), 93.7% support
Amneal Pharmaceuticals, Inc.2026-05-06Election of Directors: Deb AutorAgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 92.3% support
Amneal Pharmaceuticals, Inc.2026-05-06Election of Directors: J. Kevin BuchiAgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 90.9% support
Amneal Pharmaceuticals, Inc.2026-05-06Election of Directors: Jeff GeorgeAgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 92.3% support
Amneal Pharmaceuticals, Inc.2026-05-06Election of Directors: John KielyAgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 88.3% support
Amneal Pharmaceuticals, Inc.2026-05-06Election of Directors: Paul MeisterAgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 87.5% support
Amneal Pharmaceuticals, Inc.2026-05-06Election of Directors: Shlomo YanaiAgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 92.3% support
Show all 160
Items 26 to 160.
CompanyMeetingItemThis fundMost Nationwide fundsMgmtResult
OUTFRONT Media Inc.2026-06-03Election of Director Nominees: Angela CourtinAgainstFOR — 4 of 4 Nationwide fundsAgainstPassed (calculated), 76.3% support
OUTFRONT Media Inc.2026-06-03Election of Director Nominees: Susan M. TolsonAgainstFOR — 4 of 4 Nationwide fundsAgainstPassed (calculated), 66.4% support
CRISPR Therapeutics AG2026-06-04Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 88.1% support
CRISPR Therapeutics AG2026-06-04Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027.AgainstFOR — 4 of 4 Nationwide fundsAgainst—
CRISPR Therapeutics AG2026-06-04Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026.AgainstFOR — 4 of 4 Nationwide fundsAgainst—
Boot Barn Holdings, Inc.2025-08-27Ratification of Deloitte & Touche LLP as the independent auditor for the fiscal year ending March 28, 2026.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 97.5% support
MaxLinear, Inc.2026-05-20To approve, on an advisory basis, the compensation of our named executive officers for the year ended December 31, 2025, as set forth in the proxy statement.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 85.0% support
Excelerate Energy, Inc.2026-06-04To elect the seven director nominees named in the proxy statement as directors of the Company, each to serve for a one-year term and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, removal, retirement or disqualification: Deborah L. ByeWithholdFOR — 4 of 4 Nationwide fundsAgainstElected, 99.7% support
Excelerate Energy, Inc.2026-06-04To elect the seven director nominees named in the proxy statement as directors of the Company, each to serve for a one-year term and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, removal, retirement or disqualification: Paul T. HanrahWithholdFOR — 4 of 4 Nationwide fundsAgainstElected, 99.3% support
NMI Holdings, Inc.2026-05-14Advisory approval of NMI Holdings, Inc.'s executive compensation.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 92.5% support
SkyWest, Inc.2026-05-05Shareholder A shareholder proposal regarding collective bargaining policy.ForAGAINST — 4 of 4 Nationwide fundsAgainst—
IDEAYA Biosciences, Inc.2026-06-16To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: M. Garret Hampton, Ph.D.WithholdFOR — 4 of 4 Nationwide fundsAgainstPassed (calculated), 77.7% support
Ambarella, Inc.2026-06-26To approve on a non-binding, advisory basis, the compensation of our named executive officers.AgainstFOR — 4 of 4 Nationwide fundsAgainst—
Interface, Inc.2026-05-19Approval, on an advisory basis, of executive compensation.AgainstFOR — 4 of 4 Nationwide fundsAgainstPassed (calculated), 97.7% support
BioCryst Pharmaceuticals, Inc.2026-06-11To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accountants for 2026.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 96.7% support
Veracyte, Inc.2026-06-10The approval of an amendment to our Veracyte, Inc. 2023 Equity Incentive Plan.AgainstFOR — 4 of 4 Nationwide fundsAgainstPassed (calculated), 71.2% support
Harmony Biosciences Holdings, Inc.2026-05-14Non-binding, advisory vote on the compensation of our named executive officers pursuant to the SEC's compensation disclosure rules.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 71.8% support
Harmony Biosciences Holdings, Inc.2026-05-14Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 98.3% support
Proto Labs, Inc.2026-05-19Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.AgainstFOR — 4 of 4 Nationwide fundsAgainstPassed (calculated), 97.9% support
The Pennant Group, Inc.2026-05-14Election of Directors: Brent J. GuerisoliAgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 82.0% support
The Pennant Group, Inc.2026-05-14Election of Directors: Christopher R. ChristensenAgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 78.3% support
The Pennant Group, Inc.2026-05-14Election of Directors: John G. Nackel, Ph.D.AgainstFOR — 4 of 4 Nationwide fundsAgainstElected, 78.5% support
A-Mark Precious Metals, Inc.2025-11-12Advisory vote on executive compensationAgainstFOR — 4 of 4 Nationwide fundsAgainstPassed (calculated), 76.4% support
Rigel Pharmaceuticals, Inc.2026-05-14To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 87.5% support
SmartFinancial, Inc.2026-05-21To approve, on a non-binding advisory basis, the compensation of SmartFinancial's named executive officers as listed in these proxy materials.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 97.1% support
Cytek Biosciences, Inc.2026-06-10To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 99.6% support
Puma Biotechnology, Inc.2026-06-11Advisory (non-binding) vote to approve the compensation of Puma Biotechnology, Inc.'s named executive officers as described in the proxy statement.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 78.8% support
Puma Biotechnology, Inc.2026-06-11Ratification of the selection of KPMG LLP as independent registered public accounting firm of Puma Biotechnology, Inc. for the fiscal year ending December 31, 2026.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 97.0% support
Johnson Outdoors Inc.2026-02-26To approve a non-binding advisory proposal on executive compensation.AgainstFOR — 4 of 4 Nationwide fundsAgainst—
STRATTEC Security Corporation2025-10-15Advisory Vote to Approve Executive CompensationAgainstFOR — 4 of 4 Nationwide fundsAgainstPassed (calculated), 95.7% support
STRATTEC Security Corporation2025-10-15Ratification of Appointment of Independent Registered Public Accounting FirmAgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 96.2% support
LiveRamp Holdings, Inc.2025-08-12Approval of an increase in the number of shares available for issuance under the Company's Amended and Restated 2005 Equity Compensation Plan.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 75.2% support
Theravance Biopharma, Inc.2026-06-12Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.AgainstFOR — 4 of 4 Nationwide fundsAgainstApproved, 98.8% support
Vaxcyte, Inc.2026-06-152 wordings Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Olivier Brandicourt, M.D.WithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 87.5% support
Alkermes plc2026-05-20To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.AgainstFOR — 3 of 3 Nationwide fundsAgainst—
Praxis Precision Medicines, Inc.2026-06-10To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narratAgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 96.7% support
UiPath, Inc.2026-06-25To elect as directors the eight nominees named in the Company's proxy statement, each to hold office until our Annual Meeting of Stockholders in 2027: Daniel DinesWithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 98.8% support
UiPath, Inc.2026-06-25To elect as directors the eight nominees named in the Company's proxy statement, each to hold office until our Annual Meeting of Stockholders in 2027: June YangWithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 98.7% support
Dianthus Therapeutics, Inc.2026-05-21To approve, on an advisory basis, the compensation paid to our named executive officers; andAgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 96.0% support
Dianthus Therapeutics, Inc.2026-05-21To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeWithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 80.6% support
Erasca, Inc.2026-06-26To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Alexander W. CasdinWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 88.0% support
Erasca, Inc.2026-06-26To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Julie Hambleton, M.D.WithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 89.7% support
Erasca, Inc.2026-06-26To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Michael D. Varney, Ph.D.WithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 89.7% support
Laureate Education, Inc.2026-05-21To elect nine (9) directors, each of whom shall hold office for a one year term until the 2027 Annual Meeting of Stockholders: Andrew B. CohenWithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 79.3% support
Laureate Education, Inc.2026-05-21To elect nine (9) directors, each of whom shall hold office for a one year term until the 2027 Annual Meeting of Stockholders: Ian K. SnowWithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 75.2% support
M/I Homes, Inc.2026-05-13A non-binding, advisory resolution to approve the compensation of the named executive officers of M/I Homes, Inc.AgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 95.7% support
National HealthCare Corporation2026-05-07To consider an advisory vote on the compensation of our named executive officers.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 98.1% support
Uranium Energy Corp.2025-07-17To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.AgainstFOR — 3 of 3 Nationwide fundsAgainst—
Resideo Technologies, Inc.2026-06-03Shareholder Shareholder Proposal Regarding Shareholder Right to Act by Written Consent.ForAGAINST — 3 of 3 Nationwide fundsAgainstNot approved, 23.7% support
IDEAYA Biosciences, Inc.2026-06-16To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; andAgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 88.5% support
Customers Bancorp, Inc.2026-05-26To approve a non-binding advisory resolution on named executive officer compensation.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 67.9% support
Customers Bancorp, Inc.2026-05-26To approve an amendment to the Company's 2019 Stock Incentive Plan.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 69.8% support
United Natural Foods, Inc.2025-12-16The approval of the Fifth Amended and Restated 2020 Equity Incentive Plan.AgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 72.5% support
Flywire Corporation2026-06-02Elect three directors to serve as Class II directors until the 2029 Annual Meeting of Stockholders: Alex FinkelsteinWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 70.3% support
Flywire Corporation2026-06-02Elect three directors to serve as Class II directors until the 2029 Annual Meeting of Stockholders: Gretchen HowardWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 74.1% support
Flywire Corporation2026-06-02Elect three directors to serve as Class II directors until the 2029 Annual Meeting of Stockholders: Matthew HarrisWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 73.4% support
Pediatrix Medical Group, Inc.2026-05-07Elect nine Directors, each for a term expiring at the next annual meeting or until a successor has been duly elected and qualified: John M. Starcher, Jr.AgainstFOR — 3 of 3 Nationwide fundsAgainstElected, 64.1% support
Harmony Biosciences Holdings, Inc.2026-05-14The election of four Class III directors to serve until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Ron PhilipWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 68.5% support
Centuri Holdings, Inc.2026-05-19Election of Directors: Anne L. MariucciWithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 79.5% support
Wolverine World Wide, Inc.2026-05-07Shareholder Shareholder proposal regarding new climate change polices or practices.ForAGAINST — 3 of 3 Nationwide fundsAgainstNot approved, 10.6% support
Wolverine World Wide, Inc.2026-05-07Advisory resolution to approve executive compensation.AgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 96.6% support
Gentherm Incorporated2026-05-14Approval (on an advisory basis) of the compensation of the Company's named executive officers for the year ended December 31, 2025.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 91.6% support
Gentherm Incorporated2026-05-14Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 97.7% support
Westamerica Bancorporation2026-04-23Approve a non-binding advisory vote on the compensation of our executive officers.AgainstFOR — 5 of 6 Nationwide fundsAgainstApproved, 98.0% support
Fresh Del Monte Produce Inc.2026-06-04Approve, by non-binding advisory vote, the compensation of our named executive officers in 2025AgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 96.3% support
Fresh Del Monte Produce Inc.2026-06-04Elect two director nominees for a three-year term expiring at the 2029 Annual General Meeting of Shareholders: Lori Tauber MarcusAgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 85.5% support
Fresh Del Monte Produce Inc.2026-06-04Elect two director nominees for a three-year term expiring at the 2029 Annual General Meeting of Shareholders: Michael J. BerthelotAgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 78.6% support
Nabors Industries Ltd.2026-06-02ELECTION OF DIRECTORS: Tanya S. BederForWITHHOLD — 3 of 3 Nationwide fundsForElected, 77.7% support
Janux Therapeutics, Inc.2026-06-11To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Natasha HerndayWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 90.5% support
Monte Rosa Therapeutics, Inc.2026-06-11To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Anthony Manning, Ph.D.WithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 79.0% support
Douglas Dynamics, Inc.2026-04-29Advisory vote (non-binding) to approve the compensation of the Company's named executive officers.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 96.2% support
Mitek Systems, Inc.2026-03-03To approve, on an advisory (non-binding) basis, the compensation of our named executive officers as presented in the Proxy Statement accompanying this notice.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 81.4% support
Cytek Biosciences, Inc.2026-06-10To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or rWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 75.8% support
Neurogene Inc.2026-06-03To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 99.6% support
Gray Media, Inc.2026-05-06Election of Directors: Howell W. NewtonWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 86.2% support
Gray Media, Inc.2026-05-06Election of Directors: Lorraine McClainWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 87.8% support
Gray Media, Inc.2026-05-06Election of Directors: Richard B. HareWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 79.6% support
Gray Media, Inc.2026-05-06Election of Directors: Richard L. BogerWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 86.5% support
Gray Media, Inc.2026-05-06Election of Directors: Sterling A. Spainhour, Jr.WithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 87.8% support
Citizens Financial Services, Inc.2026-04-21Advisory vote to approve the compensation of the Company's named executive officers as disclosed in the proxy statement.AgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 82.6% support
Citizens Financial Services, Inc.2026-04-21Approval of the Citizens Financial Services, Inc. 2026 Equity Incentive Plan.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 82.1% support
Information Services Group, Inc.2026-04-24To approve, in a non-binding advisory vote, the compensation paid to the Company's named executive officers.AgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 98.7% support
Fulcrum Therapeutics, Inc.2026-06-24Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Sonja BanksWithholdFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 80.3% support
Electromed, Inc.2025-11-14To approve, on a non-binding and advisory basis, our executive compensation.AgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 93.8% support
Niagen Bioscience, Inc.2026-06-24A nonbinding advisory vote of the Company's stockholders, as recommended by the Compensation Committee and approved by the Board, on the compensation of the Company's named executive officers disclosed in the Proxy Solicitation MaterialsAgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 95.7% support
Protara Therapeutics, Inc.2026-06-12Approval of an amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive PlanAgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 58.6% support
Protara Therapeutics, Inc.2026-06-12Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy statementAgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 94.6% support
Protara Therapeutics, Inc.2026-06-12Election of three Class III directors to the Board of Directors of Protara Therapeutics, Inc., each to hold office until the annual meeting of stockholders in 2029: Barry Flannelly, Pharm.D.WithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 82.2% support
Protara Therapeutics, Inc.2026-06-12Election of three Class III directors to the Board of Directors of Protara Therapeutics, Inc., each to hold office until the annual meeting of stockholders in 2029: Jesse SheffermanWithholdFOR — 3 of 3 Nationwide fundsAgainstElected, 86.3% support
Nkarta, Inc.2026-06-10Advisory approval of the compensation paid to the company's named executive officers, as disclosed in the proxy statement.AgainstFOR — 3 of 3 Nationwide fundsAgainstApproved, 92.9% support
Select Medical Holdings Corporation2026-04-23Shareholder Non-Binding Advisory Vote on a Stockholder Proposal to provide stockholders the right to call a special meeting of stockholders at a 10% ownership threshold, if properly presented at the meeting.ForAGAINST — 3 of 3 Nationwide fundsAgainstFailed (calculated), 20.0% support
Select Medical Holdings Corporation2026-04-23Non-Binding Advisory Vote on a Company Proposal to provide stockholders the right to call a special meeting of stockholders at a 25% ownership threshold.AgainstFOR — 3 of 3 Nationwide fundsAgainst—
Select Medical Holdings Corporation2026-04-23Non-Binding Advisory Vote on the Compensation of Our Named Executive Officers.AgainstFOR — 3 of 3 Nationwide fundsAgainstPassed (calculated), 97.1% support
Viant Technology Inc.2026-06-04To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AgainstFOR — 3 of 3 Nationwide fundsAgainst—
International Bancshares Corporation2026-05-18ELECTION OF DIRECTORS: A. R. Sanchez, Jr.ForAGAINST — 4 of 5 Nationwide fundsForElected, 85.9% support
EPAM Systems, Inc.2026-05-21To approve an amendment to the EPAM Systems, Inc. 2025 Long Term Incentive Plan to add 4,000,000 additional shares.AgainstFOR — 4 of 6 Nationwide fundsAgainstApproved, 80.1% support
Praxis Precision Medicines, Inc.2026-06-10To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: William YoungWithholdFOR — 3 of 4 Nationwide fundsAgainstPassed (calculated), 85.5% support
CRISPR Therapeutics AG2026-06-04Re-election of Douglas A. Treco, Ph.D.ForAGAINST — 3 of 4 Nationwide fundsForElected, 91.1% support
Boot Barn Holdings, Inc.2025-08-27Election of Directors: Lisa G. LaubeForWITHHOLD — 3 of 4 Nationwide fundsForElected, 78.3% support
MaxLinear, Inc.2026-05-20To approve an amendment and restatement of the MaxLinear, Inc. Amended and Restated 2010 Equity Incentive Plan, including approval of a new ten-year term and an increase in the number of shares reserved thereunder by 3,204,107.AgainstFOR — 3 of 4 Nationwide fundsAgainst—
CareDx, Inc.2026-06-11Approval of an amendment to the 2024 Equity Incentive Plan.AgainstFOR — 3 of 4 Nationwide fundsAgainstPassed (calculated), 66.8% support
Par Pacific Holdings, Inc.2026-04-30To approve the Par Pacific Holdings, Inc. 2026 Long-Term Incentive Plan.AgainstFOR — 4 of 6 Nationwide fundsAgainstPassed (calculated), 70.6% support
ACM Research, Inc.2026-06-10Election of Directors: David H. WangWithholdFOR — 4 of 6 Nationwide fundsAgainstElected, 95.3% support
ACM Research, Inc.2026-06-10Election of Directors: Tracy LiuWithholdFOR — 4 of 6 Nationwide fundsAgainstElected, 93.8% support
Ambarella, Inc.2026-06-26To approve an amendment and restatement of the Ambarella, Inc. 2021 Equity Incentive Plan.AgainstFOR — 3 of 4 Nationwide fundsAgainst—
BioCryst Pharmaceuticals, Inc.2026-06-11To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan.AgainstFOR — 3 of 4 Nationwide fundsAgainstApproved, 65.4% support
nLIGHT, Inc.2026-06-05Election of Class II Director: Geoffrey MooreWithholdFOR — 3 of 4 Nationwide fundsAgainstPassed (calculated), 55.6% support
The Pennant Group, Inc.2026-05-14Advisory approval of the Company's named executive officer compensationAgainstFOR — 3 of 4 Nationwide fundsAgainstApproved, 78.4% support
Janux Therapeutics, Inc.2026-06-11To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.AgainstFOR — 3 of 4 Nationwide fundsAgainstApproved, 90.3% support
Sphere Entertainment Co.2026-06-10Approval of, on an advisory basis, the compensation of our named executive officers.AgainstFOR — 3 of 5 Nationwide fundsAgainstPassed (calculated), 94.1% support
BankUnited, Inc.2026-05-21To approve the BankUnited, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan.AgainstFOR — 3 of 5 Nationwide fundsAgainstPassed (calculated), 60.2% support
ACM Research, Inc.2026-06-10Election of Directors: Charles PappisWithholdFOR — 3 of 5 Nationwide fundsAgainstElected, 90.9% support
IDT Corporation2025-12-11Election of Directors: Elaine S. YatzkanAgainstFOR — 3 of 5 Nationwide fundsAgainstElected, 91.4% support
IDT Corporation2025-12-11Election of Directors: Howard S. JonasAgainstFOR — 3 of 5 Nationwide fundsAgainstElected, 89.8% support
IDT Corporation2025-12-11Election of Directors: Irwin KatsofAgainstFOR — 3 of 5 Nationwide fundsAgainstElected, 90.9% support
Bandwidth Inc.2026-05-28To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement;AgainstFOR — 3 of 5 Nationwide fundsAgainstApproved, 75.5% support
Bandwidth Inc.2026-05-28To elect two Class III directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: David A. MorkenWithholdFOR — 3 of 5 Nationwide fundsAgainstElected, 81.9% support
Bandwidth Inc.2026-05-28To elect two Class III directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Rebecca G. BottorffWithholdFOR — 3 of 5 Nationwide fundsAgainstElected, 77.8% support
Stitch Fix, Inc.2025-12-11Election of Directors: Kofi Amoo-GottfriedWithholdFOR — 3 of 5 Nationwide fundsAgainstElected, 91.6% support
Stitch Fix, Inc.2025-12-11Election of Directors: Timothy BaxterWithholdFOR — 3 of 5 Nationwide fundsAgainstElected, 93.8% support
Designer Brands Inc.2026-06-17Amend the provisions relating to director and officer indemnification and related matters.AgainstFOR — 3 of 5 Nationwide fundsAgainstPassed (calculated), 83.9% support
Designer Brands Inc.2026-06-17Election of Directors: Peter S. CobbWithholdFOR — 3 of 5 Nationwide fundsAgainstElected, 90.0% support
Ranger Energy Services, Inc.2026-05-15To elect Class II directors to hold office until the 2029 Annual Meeting: Sean WoolvertonWithholdFOR — 3 of 5 Nationwide fundsAgainstElected, 62.0% support
Ranger Energy Services, Inc.2026-05-15To elect Class II directors to hold office until the 2029 Annual Meeting: Stuart N. BoddenWithholdFOR — 3 of 5 Nationwide fundsAgainstElected, 63.7% support
Darling Ingredients Inc.2026-05-07To elect as directors of the Company the ten nominees named in the accompanying proxy statement to serve until the next annual meeting of stockholders: Charles AdairForAGAINST — 2 of 3 Nationwide fundsForElected, 84.3% support
UiPath, Inc.2026-06-25To elect as directors the eight nominees named in the Company's proxy statement, each to hold office until our Annual Meeting of Stockholders in 2027: Philippe BotteriWithholdFOR — 2 of 3 Nationwide fundsAgainstPassed (calculated), 98.0% support
SSR Mining Inc.2026-05-07Election of Directors: Karen SwagerForWITHHOLD — 2 of 3 Nationwide fundsForElected, 83.5% support
SSR Mining Inc.2026-05-07Election of Directors: Thomas R. Bates, Jr.ForWITHHOLD — 2 of 3 Nationwide fundsForElected, 61.6% support
California Resources Corporation2026-04-30To approve, by non-binding vote, named executive officer compensation.AgainstFOR — 2 of 3 Nationwide fundsAgainstApproved, 84.8% support
Flywire Corporation2026-06-02Approve, on a non-binding, advisory basis, the compensation of Flywire Corporation's named executive officersAgainstFOR — 2 of 3 Nationwide fundsAgainstApproved, 81.6% support
Harmony Biosciences Holdings, Inc.2026-05-14The election of four Class III directors to serve until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Troy IgnelziForWITHHOLD — 2 of 3 Nationwide fundsForElected, 70.6% support
Flowco Holdings Inc.2026-05-07The election of two Class I directors to serve until the 2029 Annual Meeting of Stockholders and until his/her successors are duly elected and qualified: Joseph R. EdwardsWithholdFOR — 2 of 3 Nationwide fundsAgainstElected, 98.4% support
Rigel Pharmaceuticals, Inc.2026-05-14To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an additional 500,000 shares to the number of shares of common stock authorized for issuance under the Amended 2018 Plan.AgainstFOR — 2 of 3 Nationwide fundsAgainstApproved, 63.0% support
Puma Biotechnology, Inc.2026-06-11Election of directors to serve for a one-year term: Troy E. WilsonForWITHHOLD — 2 of 3 Nationwide fundsForPassed (calculated), 85.8% support
Viant Technology Inc.2026-06-04To elect two Class II directors, to hold office until our Annual Meeting of Stockholders in 2029 and until their successors are duly elected and qualified, or until their earlier death, resignation or removal: Chris VanderhookWithholdFOR — 2 of 3 Nationwide fundsAgainst—

Download all 160 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 94.3% of this fund’s 2,340 such votes could be given a sector; the other 133 (5.7%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Consumer Discretionary45861.3%
Finance44200.0%
Health Care40410.2%
Industrials25431.2%
Technology18121.1%
Real Estate16500.0%
Utilities10800.0%
Energy9700.0%
Consumer Staples3412.9%
Basic Materials2800.0%
Telecommunications1900.0%
Miscellaneous1700.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1,6131
Say-on-Pay2832
Audit-related2600
Compensation940
Corporate Governance608
Extraordinary Transactions260
Capital Structure240
Shareholder Rights and Defenses50
Environment or Climate11
Human Rights or Human Capital/workforce11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Par Pacific Holdings, Inc.April 30, 2026$1M140
DiamondRock Hospitality CompanyApril 28, 2026$1M100
Tompkins Financial CorporationMay 19, 2026$1M130
CBL & Associates Properties, Inc.May 21, 2026$1M90
Pediatrix Medical Group, Inc.May 7, 2026$1M120
ACI Worldwide, Inc.June 2, 2026$1M110
OUTFRONT Media Inc.June 3, 2026$1M120
Mercantile Bank CorporationMay 21, 2026$1M140

Notable votes against management

MeetingCompanyProposalFundMgmt
March 9, 2026Sanmina CorporationTo consider and vote upon the stockholder proposal entitled "Independent Board Chairman," requesting that the Board of Directors adopt a policy and amend governing documents as necessary in order that two separate people hold the office of the Chairman and the office of the CEO. Shareholder proposalForAgainst
April 29, 2026BorgWarner Inc.Vote on stockholder proposal regarding action by written consent. Shareholder proposalAgainstFor
May 1, 2026Ryder System, Inc.To vote, on an advisory basis, on a shareholder proposal regarding an independent board chair. Shareholder proposalForAgainst
April 22, 2026Dana IncorporatedShareholder proposal to require an independent Board Chairman. Shareholder proposalForAgainst
May 5, 2026SkyWest, Inc.A shareholder proposal regarding collective bargaining policy. Shareholder proposalForAgainst
June 3, 2026Resideo Technologies, Inc.Shareholder Proposal Regarding Shareholder Right to Act by Written Consent. Shareholder proposalForAgainst
May 7, 2026Wolverine World Wide, Inc.Shareholder proposal regarding new climate change polices or practices. Shareholder proposalForAgainst
April 30, 2026Ingles Markets, IncorporatedTo elect two directors to serve until the Company's 2027 annual meeting of shareholders and until their successors are duly elected and qualified: SUMMER ROAD NOMINEE: Rory A. Held Shareholder proposalForAgainst
May 26, 2026El Pollo Loco Holdings, Inc.A Shareholder Proposal requesting the Adoption of a Majority Voting Standard for the Election of Directors in Uncontested Elections. Shareholder proposalForAgainst
May 21, 2026EPAM Systems, Inc.To hold an advisory vote on a stockholder proposal, entitled "Give Shareholders an Ability to Call for a Special Shareholder Meeting." Shareholder proposalForAgainst
May 21, 2026Constellium SEAdvisory (non-binding) vote to hold an advisory (non-binding vote) on the compensation of the Company's named executive officers every two yearsAgainstFor
May 21, 2026Constellium SEAdvisory (non-binding) vote to hold an advisory (non-binding vote) on the compensation of the Company's named executive officers every three yearsAgainstFor

Contested meetings

Meetings with a proxy contest or competing nominees (2 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

2,368 ballot items at 283 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Nationwide Bailard Cognitive Value Fund (NWHDX) voted at 283 shareholder meetings of 279 companies, on 2,368 ballot items in all. Where management made a recommendation, the fund followed it on 99.4% of the items and voted against it 13 times. Its most frequent area of disagreement was corporate governance (8 of its votes against management). It voted on 11 shareholder proposals. It voted FOR the board's own proposals less often than Nationwide's funds as a whole (85.7% against 94.0%). It voted differently from most Nationwide funds on 160 items. 2 of its meetings were contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Nationwide’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.